Arsil%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520dx

# Arsil (Silymarin/Silybin) ## Overview Arsil is a standardized extract of *Silybum marianum* (milk thistle), primarily containing the flavonolignan silybin. It is classified as a dietary supplement/hepatoprotective agent. Clinical evidence regarding efficacy is mixed; it is not FDA-approved for the treatment of any specific medical condition. ## Primary Indications * Hepatoprotective agent (adjunct therapy for chronic liver disease, cirrhosis, or toxic liver damage). * Investigational use: Supportive treatment for *Amanita phalloides* (death cap mushroom) poisoning. ## Adult Dosing * **Hepatoprotective (Chronic):** 140 mg to 200 mg orally 2–3 times daily (standardized to 70–80% silymarin). * **Mushroom Poisoning (IV):** Silibinin (Legalon SIL) 20–50 mg/kg/day administered as a continuous IV infusion over 24 hours. *Note: IV formulation availability is highly restricted and depends on local poison control center protocols.* ## Pediatric Dosing * **General Hepatoprotective:** Safety and efficacy are not established. Use is generally discouraged due to lack of standardized pediatric pharmacokinetic data. * **Mushroom Poisoning:** 20–50 mg/kg/day IV. Dosing must be guided by specialized toxicological consultation. ## Dose Adjustments * **Renal/Hepatic Impairment:** No standard adjustment guidelines exist. Use with caution in severe hepatic impairment, as therapeutic efficacy is unproven. ## Contraindications * Known hypersensitivity to Asteraceae/Compositae family plants (e.g., ragweed, marigolds, daisies). * Pregnancy/Lactation: Insufficient safety data; generally recommended to avoid. ## Adverse Effects * **Gastrointestinal:** Diarrhea (most common), abdominal bloating, nausea, dyspepsia. * **Allergic:** Rare reports of pruritus, urticaria, or anaphylaxis in sensitive individuals. * **Endocrine:** Possible estrogenic effects; use with caution in hormone-sensitive conditions (e.g., breast cancer, endometriosis). ## Key Drug Interactions * **CYP450 Substrates:** May inhibit CYP2C9 and CYP3A4; potential for increased serum concentrations of drugs with a narrow therapeutic index (e.g., warfarin, phenytoin, cyclosporine). * **Antidiabetic Agents:** May cause additive hypoglycemic effects. Monitor blood glucose closely. ## Monitoring * **Hepatic:** Baseline and periodic liver function tests (ALT, AST, ALP, bilirubin). * **Clinical:** Monitor for signs of allergic reaction or gastrointestinal distress. * **Drug-Drug:** Monitor INR if used concurrently with warfarin. ## Clinical Pearls * **Bioavailability:** Silymarin is notoriously poorly absorbed; standardized formulations (e.g., phytosome complexes) are often used to improve oral bioavailability. * **Regulation:** As a supplement, purity and potency vary significantly between brands. Recommend USP-verified or high-quality professional-grade products. * **Treatment:** Should never replace established frontline medical therapy for acute liver failure or viral hepatitis. *** **Disclaimer:** This information is for educational purposes only. Silymarin is not a substitute for conventional medical therapy. Consult current institutional protocols, primary literature, and official prescribing information (package inserts) before clinical administration. Always review current medication reconciliation before initiating new supplements.